Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is one of the Best Stocks to Buy for the Next 3 Months According to Hedge Funds. On September 2, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) with a price target of $80. The analyst noted the company’s recent deal with Novartis as a strong vote of confidence. The deal brings $200 million upfront, which has the potential to lead to a $2 billion milestone. Trucchio highlighted that this deal valid ...

Q2:2025 Business Update and Financial Results July 30, 2025 Nasdaq: IONS 1 On Today's Earnings Call Eugene Schneider, M.D. Chief Clinical Development Officer Eric Swayze, Ph.D. Executive Vice President, Research 2 Brett Monia, Ph.D. Chief Executive Officer Kyle Jenne Chief Global Product Strategy Officer In this presentation, unless the context requires otherwise, "Ionis," "Company," "we," "our," and "us" refers to Ionis Pharmaceuticals and its subsidiaries. Ionis Pharmaceuticals® is a registered trademark ...